Insight Molecular Diagnostics Inc. — Director's Dealing 2023

Jun 27, 2023

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Oncocyte Corp (OCX)
CIK: 0001642380
Period of Report: 2023-06-23

Reporting Person: Arno Andrew (Director)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2023-06-23	Common Stock, no par value	A	30000	—	Acquired	703133	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2023-06-23	Option to Purchase Common Stock	$0.20	A	135000	Acquired	2033-06-23	Common Stock (135000)	Direct

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock, no par value	156084	Indirect
Common Stock, no par value	156084	Indirect

Footnotes

F1: The Restricted Stock Units shall vest one year from the date of grant, subject to the Reporting Person's continued service as a director of the Issuer from the date of grant until the vesting date or, if earlier, until the next annual meeting of shareholders.

F2: These shares of the Issuer's common stock, no par value ("Common Stock"), are held by JBA Investments LLC ("JBA"). The Reporting Person is the Manager of JBA and in such capacity has the right to vote and dispose of securities held by JBA.

F3: These shares of Common Stock are held by MJA Investments LLC ("MJA"). The Reporting Person is the Manager of MJA and in such capacity has the right to vote and dispose of securities held by MJA.

F4: Options shall vest one year from the date of grant, subject to the Reporting Person's continued service as a director of the Issuer from the date of grant until the vesting date or, if earlier, until the next annual meeting of shareholders.